Chris Witowski, PhD

📉 🍄BUY Low, Sell High Psychedelics? The entire psychedelics sector remains deeply underwater from its pandemic-era highs, down >80% across $ATAI, $CMPS, and the $PSIL ETF. 🗣️But that might be exactly why it deserves another look. 🧠 New data from $ATAI / Beckley show that fast-acting intranasal 5-MeO-DMT (BPL-003) can deliver durable depression relief in just a 2-hour clinic session. That changes the economics: short sessions mean scalable models, like $JNJ’s Spravato blockbuster. 🇺🇸 Political momentum is real: MAHA advocates are vocal, FDA leadership is signaling support, and a path to P3 is now in motion. 🎯 Compass $CMPS is still weighed down by long psilocybin sessions and meh Ph3. But $ATAI is emerging with a cleaner story, tighter trial design, and asymmetric upside. 🔬 Gilgamesh is another sleeper to watch, with novel neuroplasticity assets designed to avoid the hallucination entirely, offering a pharma-friendly path if data hold up. This is what early-stage contrarian biotech looks like: 📉 Sentiment wrecked 🧪 Data improving ⏱️ Timelines compressing 💰 TAM enormous Buy when you can’t pitch it at dinner. wsj.com/health/pharma/psyche…

Psilera prepares for the clinical advancement of its lead #neuroplastogen #PSIL-006 by appointing a VP of #ClinicalDevelopment. Read the press release for full details: prn.to/3UCxhpV

By the end of 2027 we very likely will have FDA-approved psilocybin, MDMA, and LSD. Wild.

Folarin Balogun will be available to play the USMNT’s round of 16 match against Belgium, with his one-game red-card ban that he received against Bosnia and Herzegovina suspended. Article 27 of FIFA’s disciplinary code states that “the judicial body may decide to fully or partially suspend the implementation of a disciplinary measure.” nyti.ms/3RkeoH5

Psilera Debuts Novel Synthetic Platform to Aid Discovery of #Neuroplastogens in New #Publication The peer-reviewed research identifies #4BrDMT as a synthetic building block to expand and diversify our #neuroplastogen #DrugDiscovery capabilities. prnewswire.com/news-releases…

#Oppenheimer's #CNS and #NeuroMuscular Summit in #Miami is today! A highlight of the day's agenda will be a panel featuring Chris Witowski, PhD, and industry KOLs discussing the industry and solutions for the future. #Innovation #Neuroplastogens #Psychedelics #DrugDiscovery

One month until #BIOConvention: where #biotech & #biopharma meet for #partnering and #innovation. The team will be in #SanDiego sharing the latest #data from Psilera's #nextgeneration #psychedelic and #neuroplastogen pipeline. Email [email protected] to schedule a meeting.

Guard of Honour then Budapest ❤️🙏🏽

The Arsenal. Your Premier League champions.

Co-Founder and CEO Chris Witowski, PhD, is a featured panelist at #Oppenheimer's #CNS Focus Event in #Miami 6/10/26 To meet with him and learn the latest about our #neuroplastogen pipeline, email us at [email protected] #Innovation #Psychedelics #DrugDiscovery #MindfulMedicine

Following President Trump’s directive to accelerate medical treatments for serious mental illnesses, FDA announced major steps to support the development of serotonin-2A agonists & related products—a class of medications historically referred to as "psychedelic" drugs. ✅ National priority vouchers for psilocybin (for treatment-resistant depression and major depressive disorder) ✅ National priority voucher for methylone (for post-traumatic stress disorder) ✅ First-ever noribogaine study authorized for alcohol use disorder ✅ Advancing guidance for sponsors developing these products Learn more: fda.gov/news-events/press-an…

@Psilera is bolstered by the #ExecutiveOrder signed in support of advancing #psychedelictherapies to help patients in need! prnewswire.com/news-releases… #Psychedelics #Psilocybin #Neuroplastogens #DrugInnovation #DrugDevelopment #MindfulMedicine

There's never been an investment like the investment in railroads. (This graph has a log scale!)

President Trump Delivers an Address to the Nation, Apr. 1, 2026 nitter.gq/i/broadcasts/1yKAPMqQd…

I am Sam Hazen, CEO of HCA Healthcare. The largest for-profit hospital system in the United States. One hundred and eighty-two hospitals. Twenty states. I oversee a spreadsheet called the chargemaster. It has 42,000 line items. Each line item is a price. The prices are not real. I need to be precise about that. They are not estimates. Not approximations. Not market rates. They are anchors. An anchor is a number you set high so that every negotiated discount feels like a victory. No relationship to cost. No relationship to value. A relationship to leverage. My team sets the anchors. That is the job. The price is correct. Take a drug. Keytruda. Immunotherapy. Treats sixteen types of cancer. The manufacturer charges approximately $11,000 per dose. That is the acquisition cost. What the hospital pays. My team enters it into the chargemaster. They do not enter $11,000. They enter $43,000. That is the gross charge. The gross charge is a fiction. No one pays it. No one is expected to pay it. The gross charge exists so that when Blue Cross negotiates a 68% discount, they pay $13,760, and the contract says "68% discount" and both parties feel the transaction was rigorous. A 68% discount on a fictional price produces a real price that is 25% above acquisition cost. That margin is where I live. My 2025 compensation was $26.5 million. Eighty percent of my bonus is tied to EBITDA. Earnings Before Interest, Taxes, Depreciation, and Amortization. It is also earnings before the patient opens the bill. Same dose of Keytruda at the hospital across town. Gross charge: $12,000. Blue Cross rate: $10,200. Same drug. Same dose. Same needle. Same cancer. Different spreadsheet. The CMS transparency data showed the ratio between the highest and lowest negotiated price for the same drug at the same hospital can reach 2,347 to one. Not 2x. Not 10x. Not 100x. Two thousand three hundred and forty-seven to one. For the same thing. In the same building. On the same Tuesday. The price is correct. Every drug in the chargemaster has twelve prices. Twelve. Gross charge. Medicare rate. Medicaid rate. Blue Cross. Aetna. Cigna. UnitedHealth. Humana. Workers' comp. Tricare. Auto insurance. And the self-pay rate. The self-pay rate is for the person without insurance. It is the gross charge. The fictional number. The anchor. The person without insurance pays the number that was designed to be negotiated down from. They pay the ceiling because they have no one to negotiate on their behalf. Same drug. Same chair. Same nurse. They pay the price that no insurer in the country would accept. I maintain a file. CDM line item 637-4892-PKB. Saline flush. Sodium chloride 0.9%. Acquisition cost: $0.47. We charge $87. That is an 18,410% markup. The saline flush is used before and after every IV infusion. A chemo patient receiving twelve cycles will be charged $87 for saline fourteen times per visit. I know the math. My team built the math. The math is the job. The price is correct. In 2021, the federal government required hospitals to publish their prices. The Hospital Price Transparency Rule. Machine-readable file. Gross charges. Discounted cash prices. Payer-specific negotiated rates. We complied. We posted the file. The file is a 9,400-row CSV on our website under "Patient Financial Resources." Four clicks from the homepage. Column F: "CDM_GROSS_CHG." Column J: "DERV_PAYERID_NEGRATE." My team designed the column headers. They designed them to comply. They did not design them to communicate. CMS reported 93% of hospitals now post a file. Compliance. But only 62% of the posted data is usable. That gap is where we operate. We are compliant. The data is published. The data is incomprehensible. A researcher downloaded our file. She spent three weeks cleaning it. She called the billing department for clarification on 340 line items. They transferred her four times. The fourth transfer was to a voicemail box that was full. She published her analysis anyway. Cardiac catheterization lab charges: $8,200 to $71,000 for the same procedure depending on the payer. The report received eleven views on our press monitoring dashboard. I saw it. I did not forward it. On April 1, a new CMS rule takes effect. Hospital CEOs must personally attest — by name, encoded in the machine-readable file — that the pricing data is "true, accurate, and complete." My name. Sam Hazen. In the file. Attesting that 42,000 fictional anchors are true, accurate, and complete. They are complete. I will give them that. Forty-two thousand line items is nothing if not complete. A new analyst read the transparency data. She asked why the same MRI costs $450 for Medicare and $4,200 for Aetna in the same building on the same machine. I told her the rates reflect negotiated contractual agreements between the payer and the facility. She said that doesn't explain the difference. I told her the difference IS the contractual agreement. She said that sounds like the price is arbitrary. I told her the price is the result of a rigorous, multi-variable analysis that accounts for acuity, case mix, regional market dynamics, and payer contract terms. She asked if I could show her the analysis. I told her the analysis is proprietary. The analysis does not exist. The analysis is my team, in Q4, adjusting the chargemaster upward by the percentage the CFO wrote on a sticky note. The sticky note this year said "6-8%." They chose 7.4% because it is between six and eight and it has a decimal, which makes it look calculated. She stopped asking. The price is correct. My insurance. The executive health plan. Not in the chargemaster. Administered separately. I do not pay the gross charge. I do not pay the negotiated rate. I pay a $20 copay for services at our own facilities. Gross charge for my treatment: $14,200. Insured rate for our largest commercial payer: $8,600. I pay $20. The executive health plan was designed by the Chief Human Resources Officer and approved by the compensation committee. I was not on the compensation committee. I was a beneficiary of it. That is a different thing. I benefit from the system I price. I price the system I benefit from. These are two separate facts that happen to involve the same person. HCA Healthcare was named the Most Admired Company in our industry by Fortune magazine for the twelfth consecutive year. That was February. The same month I sold $21.5 million in company stock and purchased zero shares. Fortune did not ask about the chargemaster. I am Sam Hazen, CEO of HCA Healthcare. I have 42,000 prices in a spreadsheet across 182 hospitals. None of them are real. All of them are charged. Same drug: $12,000 or $43,000. Depends on which spreadsheet. Which building. Which contract. Which page of which PDF. The patient who has no contract pays the most. The researcher who found the discrepancy got a voicemail box that was full. The analyst who asked why stopped asking. The executive who prices the system pays $20. On April 1, I will personally attest that this is true, accurate, and complete. The price is correct. The price has always been correct. I am the price.

For quality of life, it is better to err on the side of being an optimist and wrong, rather than a pessimist and right